Mometasone
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Mometasone |
| DrugBank ID | DB00764 |
| Brand Names (EU) | Mometasone |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.36% |
Approved Indication (EMA)
Enerzair Breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary cutaneous T-cell lymphoma | 99.36% | DL |
| 2 | Crohn’s colitis | 98.81% | DL |
| 3 | myelodysplastic syndrome | 98.34% | DL |
| 4 | refractory cytopenia of childhood | 98.06% | DL |
| 5 | unclassified myelodysplastic syndrome | 97.94% | DL |
| 6 | partial deletion of the long arm of chromosome 5 | 97.86% | DL |
| 7 | cystic teratoma | 97.79% | DL |
| 8 | spinal cord dermoid cyst | 97.75% | DL |
| 9 | aregenerative anemia | 97.75% | DL |
| 10 | disease of orbital part of eye adnexa | 97.73% | DL |
| 11 | severe congenital hypochromic anemia with ringed sideroblasts | 97.71% | DL |
| 12 | renin-angiotensin-aldosterone system-blocker-induced angioedema | 97.69% | DL |
| 13 | dermoid cyst of ovary | 97.62% | DL |
| 14 | disease of orbital region | 97.41% | DL |
| 15 | nephrotic syndrome | 97.22% | DL |
| 16 | granulomatous slack skin disease | 97.21% | DL |
| 17 | Sezary syndrome | 97.13% | DL |
| 18 | primary cutaneous B-cell lymphoma | 96.98% | DL |
| 19 | folliculotropic mycosis fungoides | 96.69% | DL |
| 20 | mycotic corneal ulcer | 96.39% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.